GnRH-I antagonists also have marked antiproliferative activity in most endometrial, ovarian, and breast cancer cell lines tested in vitro, indicating that the dichotomy of GnRH agonists and antagonists might not apply to the GnRH system in cancer cells [7-11]. The gene discussed is GNRH1; the disease is cancer.